Biosynthetic pathway for carnosine synthesis catalyzed by carnosine synthase, with beta-alanine as the rate-limiting substrate. (None established; occasionally referred to as the “carnosine synthesis pathway,” but no formal abbreviation exists in genetics or pharmacology literature.)

The beta-alanine-sensitive carnosine synthesis pathway encompasses the biosynthetic conversion of beta-alanine and histidine to carnosine within muscle cells, a process catalyzed by the enzyme carnosine synthase (encoded by genes such as CARNS1 and ATPGD1). Beta-alanine availability is the limiting factor in this process; oral supplementation reliably increases intramuscular carnosine levels, which confers improved buffering of protons (H^+) during high-intensity exercise, scavenging of reactive oxygen species, and potential protection against deleterious aldehydes. While beta-alanine and carnosine are popular ergogenic aids, and the pathway is well understood in sports science, it is not recognized as a classical drug target. There are no selective inhibitors or activators beyond substrate supplementation, and all targeted interventions to date utilize nutritional modulation rather than pharmaceuticals. The pathway is not implicated in major disease contexts outside muscular performance or aging, and no established adverse biological effects have been reported in humans under recommended supplementation regimens.

Other names

Carnosine biosynthetic pathwayBeta-alanine-carnosine axisCarnosine synthetase pathway

Supplementation of beta-alanine increases intracellular beta-alanine availability, thereby enhancing carnosine synthesis via carnosine synthase. Improved muscle carnosine content leads to greater intracellular buffering capacity, reduced acidosis during anaerobic exercise, and potentially greater contractile performance.